Navigation Links
ACP recommends Stage 3 Meaningful Use focus on measuring improvements in health outcomes

PHILADELPHIA, January 15, 2013 -- Stage 3 Meaningful Use measures need to focus more on measuring improvements in patient health outcomes rather being than a large and growing collection of functional measures, the American College of Physicians (ACP) says in a letter submitted to the Health Information Technology Policy Committee (HITPC).

While praising the HITPC and its Meaningful Use Work Group for their diligence and hard work in developing recommendations for the Meaningful Use portion of the EHR Incentive Program, ACP noted that the proposed Stage 3 measures appear nearly identical in structure to those in previous stages.

"Stage 3 of Meaningful Use should encourage patients and practices to innovate, discovering creative ways to use the certified EHR technology they worked so hard to implement in Stages 1 and 2 and determining what has the greatest beneficial impact on the healthcare quality and value for patients, families and communities," said Michael H. Zaroukian, MD, PhD, FACP, FHIMSS, chair of ACP's Medical Informatics Committee and author of ACP's letter.

"A number of the proposed Stage 3 measures necessitate significant increases in clinical documentation, involve new and potentially complex workflows, are likely to be difficult for many eligible professionals to understand and implement, or depend on technologies that are not yet widely deployed or shown to be usable in busy practices," he added.

ACP's letter included the following specific concerns and suggestions:

  • Do not introduce new functions without appropriate testing.

  • Choose additional EHR provider note documentation requirements wisely and reduce existing requirements that do not add value.

  • Require usability testing with a specific focus on reducing data collection burdens.

  • Do not add functional requirements that have not been adequately defined.

  • Understand the implications of intensively focusing vendor programming capacity on Meaningful Use requirements, leaving them with little capacity to optimize the expanded capabilities added to meet Stage 1 and 2 certification criteria.

  • Consider the direct and indirect cost implications to EPs when adding new Meaningful Use requirements.

"We believe the some of the proposed Stage 3 requirements are likely to result in new, inefficient workflows and activities that shift physician focus away from the intended goal of patient-centered care and toward an excessive focus data collection for purposes that conflict with the physician's sense of what is most important for quality, safety, and value," Dr. Zaroukian said.

ACP noted its support of the comments offered by HIMSS Electronic Health Record Association (EHRA). In particular, ACP supports the following EHRA recommendations:

  • Focus primarily on encouraging and assisting providers to take advantage of the substantial capabilities established in Stages 1 and especially Stage 2, rather than adding many new meaningful use requirements and product certification criteria.

  • Given recent experience with Stage 2, reconsider and extend the timeline for initiating Stage 3.

  • Meaningful use and functionality changes for Stage 3 should focus on interoperability as a priority area.

  • Invest in quality measure alignment, infrastructure, and standards.

ACP also asked the HITPC to consider previous comments about Stage 2 for its final recommendations regarding Stage 3 Meaningful Use measures.

Contact: Steve Majewski
American College of Physicians

Related medicine news :

1. American Cancer Society recommends informed decision making in lung cancer screening
2. FDA Panel Recommends Against 1st Drug for Chronic Fatigue Syndrome
3. VCU medical team recommends preventive antibiotic for COPD sufferers
4. APA task force recommends treatment guidelines and position statements on transgender persons
5. Task force recommends new lung cancer screening guidelines
6. Study Recommends Putting Your Left Face Forward
7. Study recommends ways to evaluate end-of-life care in nursing homes
8. Comparable patterns of failure between SBRT, lobectomy or pneumonectomy for stage I NSCLC
9. Fox Chase researchers discover novel role of the NEDD9 gene in early stages of breast cancer
10. Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
11. MCG faculty member, former hostage returns to Kuwait as Fulbright Scholar
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: